Literature DB >> 2551214

Fluconazole (UK-49,858) treatment of candidiasis in normal and diabetic rats.

M A Fisher1, P G Lee, W F Tarry.   

Abstract

Fluconazole (UK-49,858), a new oral bistriazole antifungal agent, was compared with amphotericin B in the treatment of established systemic infection with Candida albicans in normal and diabetic rats. In normal rats, oral fluconazole at 10 mg/kg per day for 7 days reduced Candida colony counts in the kidneys and livers as well as amphotericin B did and was nearly as effective as amphotericin B in a 21-day treatment trial. There was no further reduction in Candida colony counts when normal rats were treated with fluconazole at 40 mg/kg twice a day for 7 days. In streptozotocin-induced diabetic rats, fluconazole at 20 mg/kg per day for either 7 or 21 days compared favorably with amphotericin B in efficacy. Results of our study suggest that oral fluconazole may be useful in the treatment of established disseminated candidiasis in normal as well as diabetic hosts.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2551214      PMCID: PMC176059          DOI: 10.1128/AAC.33.7.1042

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Reversible adrenal insufficiency induced by ketoconazole.

Authors:  W S Tucker; B B Snell; D P Island; C R Gregg
Journal:  JAMA       Date:  1985-04-26       Impact factor: 56.272

2.  Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice.

Authors:  P F Troke; R J Andrews; K W Brammer; M S Marriott; K Richardson
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

3.  Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits.

Authors:  J R Perfect; D V Savani; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

4.  High-dose ketoconazole therapy and adrenal and testicular function in humans.

Authors:  A Pont; J R Graybill; P C Craven; J N Galgiani; W E Dismukes; R E Reitz; D A Stevens
Journal:  Arch Intern Med       Date:  1984-11

5.  Candidiasis in cancer patients.

Authors:  G P Bodey
Journal:  Am J Med       Date:  1984-10-30       Impact factor: 4.965

Review 6.  Urinary tract infections due to Candida albicans.

Authors:  J F Fisher; W H Chew; S Shadomy; R J Duma; C G Mayhall; W C House
Journal:  Rev Infect Dis       Date:  1982 Nov-Dec

7.  Association of infection due to Candida albicans with intravenous hyperalimentation.

Authors:  J Z Montgomerie; J E Edwards
Journal:  J Infect Dis       Date:  1978-02       Impact factor: 5.226

8.  Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes.

Authors:  K Richardson; K W Brammer; M S Marriott; P F Troke
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

9.  Experimental Candida albicans, Staphylococcus aureus, and Streptococcus faecalis pyelonephritis in diabetic rats.

Authors:  L Raffel; P Pitsakis; S P Levison; M E Levison
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

10.  Candida infections in surgical patients.

Authors:  P K Marsh; F P Tally; J Kellum; A Callow; S L Gorbach
Journal:  Ann Surg       Date:  1983-07       Impact factor: 12.969

View more
  4 in total

1.  Eucalyptus globulus (eucalyptus) treatment of candidiasis in normal and diabetic rats.

Authors:  Mohammad Bokaeian; Alireza Nakhaee; Bita Moodi; Hossein Ali Khazaei
Journal:  Iran Biomed J       Date:  2010-07

2.  Effects of amphotericin B and fluconazole on the extracellular and intracellular growth of Candida albicans.

Authors:  E W van Etten; N E van de Rhee; K M van Kampen; I A Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

3.  Activity of MS-8209, a nonester amphotericin B derivative, in treatment of experimental systemic mycoses.

Authors:  L Saint-Julien; V Joly; M Seman; C Carbon; P Yeni
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

4.  Nanoparticle formulation increases Syzygium cumini antioxidant activity in Candida albicans-infected diabetic rats.

Authors:  Paula E R Bitencourt; Lariane O Cargnelutti; Carolina S Stein; Raquel Lautenchleger; Luana M Ferreira; Manuela Sangoi; Laura Denardi; Raphaela M Borges; Aline Boligon; Rafael N Moresco; Letícia Cruz; Régis A Zanette; Sydney H Alves; Maria Beatriz Moretto
Journal:  Pharm Biol       Date:  2017-12       Impact factor: 3.503

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.